2008 In Review: China’s Major Legal And Regulatory Changes For Health-Care Sector
This article was originally published in The Pink Sheet Daily
Executive Summary
SFDA merger into Ministry of Health and passage of Anti-Monopoly Law among major events whose impacts will be felt in years to come.
You may also be interested in...
China’s Supreme Court States Doctors Accepting Bribes Can Be Criminally Prosecuted
BEIJING - China's Supreme People's Court has issued a legal document that will make it easier and more likely for doctors accepting bribes to be prosecuted under the country's criminal law
China’s State FDA Loses Independence in Merger With Ministry Of Health
BEIJING - In a major revamping of China's drug regulatory system, China's State FDA will lose part of its rule-making authority during an ongoing merger with the Ministry of Health
Global Pharma Giants Concered About China’s New Anti-Monopoly Law
BEIJING - Leading executives at multinational firms operating in China, including some pharmaceutical giants, are concerned that the country's new anti-monopoly law could be used to counter strong market positions or to forced licensing of innovative products to competitors